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ABstrAct
Background: Blood transfusion is always associated with some level of risk. 
haemovigilance is a risk monitoring system integral to the practice of transfusion 
medicine whose ultimate purpose is to improve the quality and safety of transfusion 
therapy. 
Objective: to examine the contribution of haemovigilance to blood safety, including 
the approaches that some countries have taken to institute haemovigilance, and explore 
routes through which countries without such systems can achieve them. 
Data sources: the internet and journals on the topic of haemovigilance and development 
of haemovigilance systems in the english language. 
Data selection: reputable journals on the topic of haemovigilance were examined for 
abstracts and papers. Abstracts based on known credible and distinguished sources 
were selected. 
Data extraction: information on haemovigilance and the processes of developing 
haemovigilance in various countries was reviewed. 
Data synthesis: the information from selected papers and abstracts was used for 
writing this paper. 
Conclusion: varying processes for haemovigilance have been adopted by different 
countries. the more advanced systems have national/regional co ordinating mechanisms. 
Availability of haemovigilance data has given transfusion services a clear understanding 
of problems associated with transfusion that need to be solved so as to improve 
transfusion safety. Although countries in sub-saharan Africa have made considerable 
progress in enhancing blood safety in the recent past, nationally coordinated 
haemovigilance systems are lacking. focus on haemovigilance systems is considered 
the next frontier to be conquered in enhancing blood safety in the region.   
introduction
the primary objective of national blood transfusion 
services (Bts) is to  ensure safety, adequacy, 
accessibility and efficiency of blood supply through 
establishment of efficient, cost-effective and 
coordinated national systems. Bts include the chain 
of activities beginning from the mobilisation and 
selection of blood donors through blood processing 
to the transfusion of patients. The benefits of blood 
transfusion are indisputable with blood now 
being widely regarded as a drug that contributes 
to the successful management of many patients. 
the transfusion of blood, blood components and 
products is however not risk free. the threat of 
infectious agents entering the blood supply is not 
static and may evolve as new pathogens emerge 
or as old ones change their epidemiological 
pattern (1). indeed blood is well known to be an 
efficient vehicle for transmission of amongst other 
infections hepatitis, hiv and malaria. other than 
the infectious risks, transfusion may be associated 
with complications related to exposure to foreign 
antigens, altered chemical/temperature balance 
and anaphylaxis.  the term “safe blood transfusion” 
implies an outcome that is totally beneficent and 
nonmaleficent to the patient.  Safe blood practice is 
dependent on several factors including selection of 
volunteer blood donors with low risk for transfusion 
transmissible infections (tti), aseptic collection of 
blood donations, use of sensitive screening tests for 
tti, appropriate cold chain maintenance, accurate 
cross-matching, and elimination of unnecessary 
transfusions through appropriate and rational 
clinical use of blood and blood products. the 
process of monitoring for the lapses at any one of 
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these stages is termed haemovigilance. to promote 
blood safety, the world health organisation (who) 
encourages member countries to establish nationally 
coordinated haemovigilance programmes focused on 
improvement of transfusion practices (2).
Types of haemovigilance systems: haemovigilance 
is an important risk monitoring system integral 
to the practice of transfusion medicine whose 
ultimate purpose is to enhance the quality and 
safety of transfusion therapy through continuous 
improvement of transfusion standards. All processes 
throughout the chain of events from donor selection 
and phlebotomy to the post-transfusion phase are 
monitored for the occurrence of adverse or near-miss 
events. Both transfusion recipients and blood donors 
should be followed up in this process so as to detect 
any immediate and long-term effects of transfusion 
and blood donation respectively. the conventional 
system for haemovigilance is event notification. 
reporting of adverse, unexpected or near miss events 
or reactions in blood donors or recipients enables 
identification of gaps in quality systems management 
and consequently prompts the search for corrective 
measures required to ensure safe blood practice. 
  A less common form of haemovigilance is the 
direct observation system, based on direct observation 
of transfusions by appropriately trained technical staff 
at the patients’ bedside and verification of adherence 
to standard operating procedures (3, 4).
  “look back” is   yet  another form of 
haemovigilance. it involves efforts to identify 
recipients of products from a particular donor usually 
after the donor is found to have a condition that may 
have put the recipients at risk of a tti such as hiv 
or hepatitis. the success of look back depends on 
well established traceability systems enabling the 
identification of the recipient of any given blood 
component and conversely the tracing all blood 
components received by a patient. whereas these 
three approaches focus on clinical outcomes of blood 
donation or transfusion, a manufacturing/industry 
quality process approach emphasizes compliance 
to standard operating procedures throughout the 
transfusion chain. 
Analysis of haemovigilance systems:  haemovigilance 
systems have been established in several countries 
with significant benefits to the BTS. Transfusing 
facilities in the usA are obliged to inform the food 
and drug Administration (fdA) of transfusion-
related deaths. hospital accrediting bodies such as 
the Joint commission on Accreditation of healthcare 
organizations (JcAho) and the college of American 
pathologists (cAp) additionally require reporting 
or at a minimum documentation of all adverse 
transfusion events. the centers for disease control 
and prevention’s national healthcare safety network 
(nhsn) recently instituted a voluntary internet 
based haemovigilance module within its broader 
biovigilance programme to track and coordinate 
national reports of adverse events in transfusion 
recipients and blood donors (5). the main cause of 
reported deaths is transfusion-related acute lung injury 
(trAli) (30%), followed by haemolytic transfusion 
reactions (16%) and bacterial contamination (16%) 
(6). retrospective analyses carried out separately by 
linden et al (6), honig and Bove (7) and sazama (8) 
and on transfusion incidents occurring in the united 
states in the 1970s-1980s concordantly found that the 
incidence of fatal acute haemolytic reactions was one 
case in every 600,000 units transfused. An analysis of 
transfusion errors in new york state in a 22-month 
period in 1990-1991 showed that 43% (45/92) of the 
errors, of which 58% occurred outside the transfusion 
structure, were due to incorrect identification of the 
patient and/or the unit of blood (6).
  two main types of risk monitoring systems exist 
in europe; the voluntary (united Kingdom, denmark, 
greece, ireland, italy) and the obligatory (france, 
germany, switzerland). in the united Kingdom 
(uK), reports are monitored through a centralised 
voluntary, anonymous and independent process 
referred to as serious hazards of transfusion (shot) 
(9,10). shot aims to educate blood transfusion 
practitioners through annual reports and to provide 
an evidence base to support decisions, guidelines, 
clinical training and improvements in transfusion 
practices. Analysis of data collected by shot on the 
occurrence of transfusion related Acute lung injury 
(trAli) linked its use of plasma from multiparous 
females leading to discontinuation of use of plasma 
from these donors (11).
  france has a national haemovigilance system 
with two separate but parallel institutions. the french 
health products safety Agency - Agence francaise de 
sécurité sanitaire des produits desanté – (Afss-Aps) 
has a regulatory function while executive functions are 
vested with etablissement francais du sang (efs) (12). 
there is a legal obligation to notify all adverse events, 
irrespective of the severity and clinical consequences 
of the error. near-miss events however, do not need 
to be reported in the uK. in the years 1994-1998, the 
french haemovigilance system recorded a mortality 
rate equivalent to that found by linden et al (6) in 
new york state, with one death for every 1,802,739 
red cell products transfused.   
  the danish registration of transfusion risks 
(dArt) is a part of the danish haemovigilance system 
that covers registration of collected, produced and 
transfused blood components, and complications in 
connection with transfusion of these. In the first five 
years of data collection in the danish haemovigilance 
system, half of the severe events (53%) followed the 
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transfusion of an incorrect blood component and the 
other half were due to immunological complications 
(43%). only 4% of the reported events concerned 
transfusion transmitted infections (tti) (13). in 
germany, every adverse transfusion reaction must 
be reported by the transfusion centres to the paul-
ehrlich-institute (pei). transfusion errors occasioned 
by inappropriate use of blood components and not 
by the properties of the product itself are however 
not reported to the pei (9, 10).
 retrospective analysis of data collected between 
1999 and 2003 at a hospital in switzerland found that 
the incidence of transfusion reactions was 4·19 per 
1000 blood products (14). whereas some countries 
report only serious events, others like france, report 
all events including “near-miss” events.  A serious 
adverse event is defined as an unintended occurrence 
associated with the collection, testing processing, 
storage and distribution of blood or blood components 
that might lead to death or life threatening, disabling 
or incapacitating conditions for patients or which 
results in, or prolongs, hospitalisation or morbidity. 
near-miss events refer to events that did not result 
in injury but had the potential to do so other than for 
recovery steps allowing for interruption and correction 
of the error(s) and dysfunction(s). data collected in 
countries with obligatory reporting systems reveals 
that the proportion of near-miss events, with respect 
to the total number of adverse transfusion events, 
is 90% (3). near-miss events are an important 
indicator of risk gaps in the transfusion system and 
present opportunities for improvement without 
any associated potential punitive measures (15). 
Voluntary reporting systems generate significantly 
fewer reports than obligatory systems.  for example 
in 2001, 8.5 notifications /100,000 blood components 
distributed in the uK were made in contrast to 325.2/ 
100,000 blood components distributed in france (3). 
This finding indicates that voluntary reporting denies 
the haemovigilance system information important to 
the enhancement of national blood safety. legislation 
in the european union (directive 2002 ec) requires 
adverse event reporting stating that “member 
states shall ensure that any serious adverse events 
(accidents and errors) related to the collecting, testing, 
processing, storage and distribution of blood and 
blood components which may have an influence on 
their quality and safety, as well as any serious adverse 
reactions observed during or after transfusion which 
may be attributed to the quality and the safety of blood 
and blood components are notified to the competent 
authority”  (16).  
  Although based on different ways of collecting 
data, the two major european haemovigilance 
systems do contain important information useful for 
comparison of the data collected, its interpretation and 
evaluation of the corrective actions taken. in contrast 
to the USA in which only fatal errors are notified, the 
european systems collect data on both fatal and non-
fatal transfusion errors.  haemovigilance systems in 
south Africa and new Zealand are modeled on the 
uK shot system. Although it has been estimated 
that 5–10% of hiv transmission in Africa is by 
contaminated blood transfusions, according to the 
who global data base on blood safety, in 2004 the 
rate of full implementation of blood policies and 
quality management systems in the who-Afro 
region was very low at 17% and 20% respectively 
(17, 18). further, a recent review of blood safety in 
sub-saharan Africa reported that many countries in 
Africa do not have an effective haemovigilance system 
(19). These findings are corroborated by a hospital 
based study in cameroon which reported that half 
of transfusions within the hospital were associated 
with an unfavorable outcome, predominantly febrile 
reactions and urticaria but also acute intravascular 
haemolysis, circulatory overload,  post-transfusion 
hiv infection and death (20). Additionally, a study 
in Kenya in 1994 estimated that 2.0% of transfusions 
transmitted hiv (21). 
Proposal for initiating haemovigilance: haemovigilance 
can be instituted through both top-down and bottom-
up approaches. in the latter approach, individual 
health facilities should institute transfusion 
safety monitoring systems and link to a centrally 
coordinated national or regional haemovigilance 
system that provides feedback to Bts and health 
ministries. whereas the blood banking and 
processing aspects can be easily monitored through 
a technical audit process, donor care and appropriate 
blood use are more effectively monitored through 
donor satisfaction surveys and peer reviews on 
appropriate blood use. this calls for a model that 
combines evaluation of both quality processes and 
clinical outcomes. peer review is best achieved 
through hospital transfusion committees (htc). 
the htc has a primary responsibility to monitor 
and evaluate the clinical use of blood within the 
health facility so as to ensure patient safety and 
judicious use of the blood supply. guidelines for 
the rational use of blood form the basis of the 
monitoring function of the htc which should also 
organise clinician awareness training programmes 
to promote strategies for rational use of blood. htcs 
monitor transfusion orders, quantities transfused, 
indications for transfusion, occurrence of adverse 
events and their investigation. At facility level, 
selection of events to be monitored may include 
haemolytic transfusion reactions, transfusion related 
lung injury (trAli), bacterial contamination, 
anaphylactic reactions, post transfusion purpura, 
well recognised ttis, emerging ttis, near miss 
events, minor and long-term morbidity and deaths 
associated with transfusion as well as processes 
such as blood donation, laboratory testing and 
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blood processing, ordering, bedside transfusion and 
blood utilization. investigations of such reactions 
and consequent corrective measures should span 
the Bts chain incorporating both the health facility 
and the national Blood transfusion services. in 
addition to the data on reactions to transfusion, 
errors of administration, overuse or unnecessary 
administration of blood and underuse or failure to 
give necessary transfusion should also be monitored. 
htcs serve to bridge the gap between blood banks 
and transfusing facilities ensuring that safe and 
efficacious transfusions are given. It has been shown 
that the implementation of transfusion audits can 
significantly reduce the inappropriate use of blood 
products (22). 
  the  second step in this approach to 
haemovigilance is the creation of a national process to 
receive and harmonize facility based haemovigilance 
reports, streamline regulations and institute changes 
beneficial to transfusion practice. Decisions on what 
aspects of haemovigilance are to be monitored at a 
national level may be guided by prevailing ttis, 
available technology and monitoring capacity. 
the probable, possible or unlikely attribution of 
transfusion to these events should be ascertained or 
excluded through a root cause analysis by a panel of 
objective reviewers. many post transfusion deaths are 
not due to the transfusion but rather consequent to 
the primary illness. for example, sazama (8) reported 
that of 355 fatalities associated with transfusion, 99 
were excluded from further review because they were 
unrelated to the transfusion process.
  thorough investigation of adverse events should 
determine where in the transfusion chain incidents 
occur, (blood bank, ward, theatre, icu or casualty), 
when incidents occur, what causes incidents, which 
products are most vulnerable and trends in occurrence 
of adverse events. this reporting system may be 
voluntary, as in the united Kingdom or enforced 
by law as in france. haemovigilance systems that 
operate with legal backing tend to achieve higher 
reporting rates (3). evaluations of voluntary and 
obligatory systems suggest that regulatory structures 
are essential for successful implementation of 
haemovigilance and result in more comprehensive 
reporting. evidence from several countries indicates 
that where outcomes of haemovigilance result 
in punitive action reporting rates are lower and 
hence systems that focus on education and process 
improvement are preferable (22).
  As a final step national haemovigilance systems 
should be linked to an international network to 
promote global blood product safety and quality. 
processes for timely collection of information, 
disseminating findings and ensuring confidentiality 
promote success. countries in sub-saharan Africa have 
made significant positive achievements in enhancing 
BTS over the last five years by implementing key 
who pillars for blood safety such as formulation of 
policies for Bts stipulating collection of blood only 
from voluntary donors, quality blood testing and 
reduction of unnecessary transfusion (23). 
conclusion
haemovigilance is a measure of compliance to and 
the effectiveness of quality management systems 
and an excellent quality indicator for the blood 
transfusion service. without haemovigilance, it is 
impossible to definitively weigh the risk associated 
with a transfusion and consequently difficult for 
clinicians to assess the benefit/risk ratio and counsel 
pre-transfusion patients accordingly. haemovigilance 
has enabled several countries to institute relatively 
simple measures to improve blood safety with success 
such as use of wrist bands for patient identification 
and exclusion of multiparous females from plasma 
and platelet donations. despite some progress 
implementation of who recommendations for blood 
safety, very few countries in Africa have formulated 
legislation to regulate practice and monitoring of blood 
transfusion.  the time is now ripe for these countries to 
focus more attention on monitoring and evaluation of 
Bts including institution of haemovigilance systems. 
to achieve this data collection, data validation and 
reporting around blood safety must be strengthened. 
evaluation of data from haemovigilance systems 
should form the basis for development of standards 
and guidelines for transfusion practice to promote 
blood safety and limit inappropriate blood use. 
Availability of haemovigilance data provides a precise 
delineation of problems associated with transfusion 
that need to be solved so as to improve transfusion 
safety. Key players in successful institution of national 
haemovigilance systems include health facility/ blood 
bank based professionals, a national coordinating 
body, regulatory/policy formulating body. 
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